FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1538458380> ?p ?o ?g. }

• W1538458380 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CABackground: A key obstacle in the treatment of cancer is resistance to targeted therapy. Recent reports suggest that growth factors and their receptors may play a role in mediating this resistance. HGF/MET signaling has been shown to play a role in mediating resistance to BRAF inhibitors in BRAF mutant melanoma. We studied the role of HGF/MET in mediating resistance to BRAF inhibition in BRAF mutant melanoma xenografts, comparing models of systemic and local HGF expression and evaluating the ability of a MET inhibitor to reverse HGF mediated resistance. The underlying mechanisms of this resistance were evaluated by monitoring changes in PI3K and MAPK signaling. Our data suggest that elevated local HGF expression may be required for resistance to BRAF inhibition in vivo and that resistance can be reversed by treatment with a MET inhibitor.Methods: To model systemic HGF expression, mice bearing G361 melanoma xenografts were treated with recombinant adeno-associated virus containing an expression cassette for human HGF (AAV-HGF) or GFP as control. Mice were treated with C-1 (10 mg/kg, QD, PO), a BRAF inhibitor, or vehicle, and tumor growth was monitored. Local HGF expression was modeled using G361 xenografts engineered to express HGF under the control of an inducible promoter (tet-HGF). Mice bearing G361 tet-HGF xenografts, with or without doxycycline, were treated and monitored as described above. A follow up study was performed in G361 tet-HGF xenografts to measure the ability of AMG 337 (20 mg/kg, BID, PO), a selective MET inhibitor, to attenuate the HGF mediated rescue of BRAF inhibition. To monitor effects on the PI3K and MAPK pathways, pAKT and pERK levels were measured in tumors. Plasma and tumor HGF levels were also measured.Results: Systemic expression of HGF via AAV-HGF treatment failed to rescue G361 xenografts from the growth inhibitory effects of C1. In contrast, local doxycycline-induced expression of HGF in mice harboring G361 tet-HGF xenografts conveyed significant (p<0.001) rescue of tumor growth, suggesting that local HGF expression may be required to mediate BRAF inhibitor resistance. Elevated pAKT and pERK levels were detected in HGF rescued tumors, suggesting that PI3K and MAPK signaling pathways play a role in conveying HGF mediated resistance. Combined treatment with AMG 337 prevented the HGF mediated rescue of BRAF inhibition, confirming the role of MET signaling in this rescue mechanism. Plasma HGF levels in mice from the systemic HGF expression groups exceeded those in the local groups (3,049 and 195 pg/mL). However, tumor HGF levels were higher in the local expression groups compared to the systemic groups (26,400 and 477 pg/mL).Conclusion: Here we demonstrate the role for HGF/MET signaling in mediating resistance to BRAF inhibitors in melanoma and suggest that monitoring HGF levels may be of clinical utility for predicting response to BRAF inhibition and in defining the opportunity for combination therapy with MET inhibitors.Citation Format: Keegan Cooke, Guo Huang, Sean Caenepeel, Hong Ma, Cherylene Plewa, Ki Jeong Lee, Angela Coxon, Paul E. Hughes, Pedro Beltran. HGF mediated resistance to BRAF inhibition in BRAF V600E mutant melanoma xenograft models. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3712. doi:10.1158/1538-7445.AM2014-3712" @default.
• W1538458380 created "2016-06-24" @default.
• W1538458380 creator A5001120662 @default.
• W1538458380 creator A5017385944 @default.
• W1538458380 creator A5017725600 @default.
• W1538458380 creator A5028290249 @default.
• W1538458380 creator A5039424521 @default.
• W1538458380 creator A5039577669 @default.
• W1538458380 creator A5053060128 @default.
• W1538458380 creator A5062898463 @default.
• W1538458380 creator A5084081712 @default.
• W1538458380 date "2014-09-30" @default.
• W1538458380 modified "2023-09-26" @default.
• W1538458380 title "Abstract 3712: HGF mediated resistance to BRAF inhibition in BRAF V600E mutant melanoma xenograft models" @default.
• W1538458380 doi "https://doi.org/10.1158/1538-7445.am2014-3712" @default.
• W1538458380 hasPublicationYear "2014" @default.
• W1538458380 type Work @default.
• W1538458380 sameAs 1538458380 @default.
• W1538458380 citedByCount "0" @default.
• W1538458380 crossrefType "proceedings-article" @default.
• W1538458380 hasAuthorship W1538458380A5001120662 @default.
• W1538458380 hasAuthorship W1538458380A5017385944 @default.
• W1538458380 hasAuthorship W1538458380A5017725600 @default.
• W1538458380 hasAuthorship W1538458380A5028290249 @default.
• W1538458380 hasAuthorship W1538458380A5039424521 @default.
• W1538458380 hasAuthorship W1538458380A5039577669 @default.
• W1538458380 hasAuthorship W1538458380A5053060128 @default.
• W1538458380 hasAuthorship W1538458380A5062898463 @default.
• W1538458380 hasAuthorship W1538458380A5084081712 @default.
• W1538458380 hasConcept C121608353 @default.
• W1538458380 hasConcept C126322002 @default.
• W1538458380 hasConcept C150903083 @default.
• W1538458380 hasConcept C170493617 @default.
• W1538458380 hasConcept C207001950 @default.
• W1538458380 hasConcept C2776996007 @default.
• W1538458380 hasConcept C2777658100 @default.
• W1538458380 hasConcept C502942594 @default.
• W1538458380 hasConcept C71924100 @default.
• W1538458380 hasConcept C86803240 @default.
• W1538458380 hasConceptScore W1538458380C121608353 @default.
• W1538458380 hasConceptScore W1538458380C126322002 @default.
• W1538458380 hasConceptScore W1538458380C150903083 @default.
• W1538458380 hasConceptScore W1538458380C170493617 @default.
• W1538458380 hasConceptScore W1538458380C207001950 @default.
• W1538458380 hasConceptScore W1538458380C2776996007 @default.
• W1538458380 hasConceptScore W1538458380C2777658100 @default.
• W1538458380 hasConceptScore W1538458380C502942594 @default.
• W1538458380 hasConceptScore W1538458380C71924100 @default.
• W1538458380 hasConceptScore W1538458380C86803240 @default.
• W1538458380 hasLocation W15384583801 @default.
• W1538458380 hasOpenAccess W1538458380 @default.
• W1538458380 hasPrimaryLocation W15384583801 @default.
• W1538458380 hasRelatedWork W1417458945 @default.
• W1538458380 hasRelatedWork W1546835108 @default.
• W1538458380 hasRelatedWork W1968752997 @default.
• W1538458380 hasRelatedWork W1982029509 @default.
• W1538458380 hasRelatedWork W1983915589 @default.
• W1538458380 hasRelatedWork W2001304515 @default.
• W1538458380 hasRelatedWork W2003091900 @default.
• W1538458380 hasRelatedWork W2020298106 @default.
• W1538458380 hasRelatedWork W2021539950 @default.
• W1538458380 hasRelatedWork W2034624764 @default.
• W1538458380 hasRelatedWork W2095950160 @default.
• W1538458380 hasRelatedWork W2150199839 @default.
• W1538458380 hasRelatedWork W2315283981 @default.
• W1538458380 hasRelatedWork W2326569921 @default.
• W1538458380 hasRelatedWork W2329621295 @default.
• W1538458380 hasRelatedWork W2329978383 @default.
• W1538458380 hasRelatedWork W2330841733 @default.
• W1538458380 hasRelatedWork W2566758544 @default.
• W1538458380 hasRelatedWork W2619254438 @default.
• W1538458380 hasRelatedWork W3179542817 @default.
• W1538458380 isParatext "false" @default.
• W1538458380 isRetracted "false" @default.
• W1538458380 magId "1538458380" @default.
• W1538458380 workType "article" @default.